Dr. Sampognaro is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
400 Parnassus Ave
San Francisco, CA 94143Phone+1 410-955-5000
Education & Training
University of California (San Francisco)Fellowship, Neuromuscular Medicine (Neurology), 2018 - 2019- University of California (San Francisco)Residency, Neurology, 2015 - 2018
Johns Hopkins University School of MedicineClass of 2014
Certifications & Licensure
CA State Medical License 2015 - 2025- American Board of Psychiatry and Neurology Neurology
- American Board of Psychiatry and Neurology Neuromuscular Medicine
Awards, Honors, & Recognition
- Inductee Alpha Omega Alpha Honor Medical Society
Publications & Presentations
PubMed
- 2 citationsApilimod dimesylate in C9orf72 amyotrophic lateral sclerosis: a randomized phase 2a clinical trial.Suma Babu, Katharine A Nicholson, Jeffrey D Rothstein, Andrea Swenson, Paul J Sampognaro
Brain. 2024-09-03 - Correction: Mutations in α-synuclein, TDP-43 and tau prolong protein half-life through diminished degradation by lysosomal proteases.Paul J Sampognaro, Shruti Arya, Giselle M Knudsen, Emma L Gunderson, Angelica Sandoval-Perez
Molecular Neurodegeneration. 2023-05-30 - 12 citationsMutations in α-synuclein, TDP-43 and tau prolong protein half-life through diminished degradation by lysosomal proteases.Paul J Sampognaro, Shruti Arya, Giselle M Knudsen, Emma L Gunderson, Angelica Sandoval-Perez
Molecular Neurodegeneration. 2023-05-02
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
